Title of paper: Treatment of chronic alopecia areata with tildrakizumab: an open-label pilot study

Authors: Karolina Louisa Suzanna Kerkemeyer, MBBS (Honours), BHlthSci, Rodney Sinclair, MBBS, MD, FACD

Corresponding author: Dr Karolina Louisa Suzanna Kerkemeyer, MBBS
Level 3, 2 Wellington Parade East Melbourne Victoria 3002
Business telephone number – +61 3 9654 2426
Business fax number – +61 3 9650 9944
E-mail address – Karolina.Kerkemeyer@sinclairdermatology.com.au

Funding sources: Sun Pharmaceutical Industries Ltd. for compassionate supply of tildrakizumab

Conflict(s) of interest statement: Professor Sinclair has served as an investigator in clinical trials sponsored by Sun Pharmaceutical Industries Ltd.

Manuscript word count: 498 words
Table count: 1
Figure count: 1
Alopecia areata (AA) is a common autoimmune disease with an estimated lifetime risk of 2.0%. Most patients experience acute AA with 1-5 circular patches of alopecia that develop in close succession and spontaneously regrow within 6-12 months. When AA persists beyond 12 months it is defined as chronic. Approximately 30% of patients develop chronic AA with the serial development of multiple patches of alopecia over many years.

A systematic review of systemic treatment for AA did not identify any reliably effective evidence-based treatments for chronic AA, and a significant number of patients are refractory to all treatment.

Tildrakizumab is a high-affinity monoclonal antibody targeting interleukin (IL)-23 p19. IL-23 induces T-helper 17 (Th17) cell proliferation that produce IL-17, a proinflammatory cytokine linked to the pathogenesis of several autoimmune conditions. Janus kinase (JAK) 2 has also been demonstrated to be an intracellular mediator of IL-23 cell surface receptor binding. Recent evidence support the role of IL-17 in the pathogenesis of AA, highlighting the potential therapeutic role by targeting IL-23.

To study the efficacy of tildrakizumab in chronic AA, patients with moderate to severe AA, refractory to systemic therapy, were enrolled in a prospective, open-label pilot study. All had a baseline Severity of Alopecia Tool (SALT) score > 35%. Prior to first dose, all patients had negative serology for human immunodeficiency virus, hepatitis B and C viruses, and for Mycobacterium tuberculosis. Tildrakizumab, 100mg, was administered subcutaneously at weeks 0, 4 and 16. Response was assessed by calculating the percent change in SALT score at week 28: no response (0%), minimal (1%-15%), partial (16%-99%), or complete (100%). Patient demographics and treatment courses are detailed in Table 1.

Five females and 4 males aged between 17 and 48 years received 3 doses of tildrakizumab. The mean age at AA onset was 14.1 years (standard deviation [SD] 7.9; range 5-33 years). The mean duration of the current episode of AA was 9.4 years (SD, 6.4; range, 2-21 years). Two patients had patchy AA, 4 had alopecia totalis (AT), and 3 patients had alopecia universalis (AU). All patients were refractory to multiple previous treatments including oral prednisolone, tofacitinib, azathioprine, intralesional steroid, and diphenylcyclopropenone (DPCP). Two patients had a partial response (Fig.1), and 8 patients had no regrowth. One
patient withdrew after 2 injections due to lack of efficacy. Adverse effects of tildrakizumab were mild and included upper respiratory tract infection and acne.

The partial response to tildrakizumab seen in 2 out of 9 participants adds to the existing literature supporting the role of IL-17 in the pathogenesis of AA. The response rate to tildrakizumab is similar to that seen with cyclosporin 4mg/kg. Limitations of this pilot study include small sample size, lack of control group, and that only patients refractory to multiple other therapies were included. The treatment protocol selected was that used to treat psoriasis which is lower than the dose used to treat hidradenitis suppurativa. Adequately powered, randomized, placebo-controlled, dose-ranging trials would be required to further examine the efficacy of tildrakizumab in AA.

References

Figure legends

**Figure 1.** Patient 5. Baseline Severity of Alopecia Tool (SALT) score 86 (left). SALT score 68 at week 28. Significant improvement not fully reflected in SALT score due to pre-existing androgenetic alopecia (right). Treatment was continued for a further 6 months, and the response maintained.
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>22</td>
<td>17</td>
<td>42</td>
<td>35</td>
<td>48</td>
<td>28</td>
<td>20</td>
<td>20</td>
<td>30</td>
</tr>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>Age of onset of AA, y</td>
<td>10</td>
<td>5</td>
<td>11</td>
<td>12</td>
<td>33</td>
<td>13</td>
<td>13</td>
<td>18</td>
<td>12</td>
</tr>
<tr>
<td>Duration of current episode of AA, y</td>
<td>6</td>
<td>3</td>
<td>21</td>
<td>8</td>
<td>15</td>
<td>10</td>
<td>5</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>Autoimmune/atopic comorbidities</td>
<td>–</td>
<td>AD</td>
<td>AD</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>AR</td>
<td>AD</td>
<td>Thyroid disease</td>
</tr>
<tr>
<td>Family history</td>
<td>–</td>
<td>–</td>
<td>AA</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>AD</td>
<td>AA</td>
<td>AD</td>
</tr>
<tr>
<td>Pattern of scalp AA</td>
<td>Totalis</td>
<td>Patchy</td>
<td>Universalis</td>
<td>Totalis</td>
<td>Patchy</td>
<td>Universalis</td>
<td>Totalis</td>
<td>Universalis</td>
<td>Totalis</td>
</tr>
<tr>
<td>Baseline SALT score, %</td>
<td>100</td>
<td>38</td>
<td>100</td>
<td>95</td>
<td>86</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>SALT score at week 28, %</td>
<td>100</td>
<td>29</td>
<td>100</td>
<td>100#</td>
<td>68</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Response to treatment</td>
<td>None</td>
<td>Partial</td>
<td>None</td>
<td>None</td>
<td>Partial</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Follow-up duration, weeks/outcome</td>
<td>28/ceased</td>
<td>28/ceased</td>
<td>28/ceased</td>
<td>12/ceased</td>
<td>28/4th injection administered</td>
<td>28/ceased</td>
<td>28/ceased</td>
<td>28/ceased</td>
<td>28/ceased</td>
</tr>
<tr>
<td>Adverse event(s)</td>
<td>URTI</td>
<td>Acne</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: AA, Alopecia areata; AD, Atopic dermatitis; AR, Allergic rhinitis; F, Female; M, Male; URTI, upper respiratory tract infection; y, year
#SALT score calculated at week 12 for patient 4
*No response (0%), minimal (1%-15%), moderate (16%-99%), complete (100%).
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Kerkemeyer, KLS; Sinclair, R

Title:
Treatment of chronic alopecia areata with tildrakizumab: an open-label pilot study

Date:
2020-03-03

Citation:

Persistent Link:
http://hdl.handle.net/11343/278568